Twist Bioscience Corporation

DB:0ME Stock Report

Market Cap: €2.4b

Twist Bioscience Valuation

Is 0ME undervalued compared to its fair value, analyst forecasts and its price relative to the market?

Valuation Score

2/6

Valuation Score 2/6

  • Below Fair Value

  • Significantly Below Fair Value

  • Price-To-Sales vs Peers

  • Price-To-Sales vs Industry

  • Price-To-Sales vs Fair Ratio

  • Analyst Forecast

Share Price vs Fair Value

What is the Fair Price of 0ME when looking at its future cash flows? For this estimate we use a Discounted Cash Flow model.

Below Fair Value: 0ME (€38.89) is trading above our estimate of fair value (€11.88)

Significantly Below Fair Value: 0ME is trading above our estimate of fair value.

Key Valuation Metric

Which metric is best to use when looking at relative valuation for 0ME?

Key metric: As 0ME is unprofitable we use its Price-To-Sales Ratio for relative valuation analysis.

The above table shows the Price to Sales ratio for 0ME. This is calculated by dividing 0ME's market cap by their current revenue.
What is 0ME's PS Ratio?
PS Ratio8x
SalesUS$312.97m
Market CapUS$2.47b

Price to Sales Ratio vs Peers

How does 0ME's PS Ratio compare to its peers?

The above table shows the PS ratio for 0ME vs its peers. Here we also display the market cap and forecasted growth for additional consideration.
CompanyForward PSEstimated GrowthMarket Cap
Peer Average9.4x
MOR MorphoSys
10.2xn/a€2.6b
BIO3 Biotest
1.5x3.6%€1.4b
FYB Formycon
13.6x33.4%€827.2m
HPHA Heidelberg Pharma
12.3x16.6%€103.9m
0ME Twist Bioscience
8x14.7%€2.5b

Price-To-Sales vs Peers: 0ME is good value based on its Price-To-Sales Ratio (8x) compared to the peer average (9.4x).

Price to Sales Ratio vs Industry

How does 0ME's PS Ratio compare vs other companies in the DE Biotechs Industry?

6 CompaniesPrice / SalesEstimated GrowthMarket Cap
CNW co.don
0.7xn/aUS$6.97m
V9Z Aceragen
0.4xn/aUS$3.12m
PA8 Paion
0.2x30.2%US$2.78m
V9Z Aceragen
0.3x-161.8%US$2.18m
0ME 8.0xIndustry Avg. 7.9xNo. of Companies6PS0612182430+
6 CompaniesEstimated GrowthMarket Cap
No more companies

Price-To-Sales vs Industry: 0ME is good value based on its Price-To-Sales Ratio (8x) compared to the European Biotechs industry average (8x).

Price to Sales Ratio vs Fair Ratio

What is 0ME's PS Ratio compared to its Fair PS Ratio? This is the expected PS Ratio taking into account the company's forecast earnings growth, profit margins and other risk factors.

0ME PS Ratio vs Fair Ratio.
Fair Ratio
Current PS Ratio8x
Fair PS Ratio3.8x

Price-To-Sales vs Fair Ratio: 0ME is expensive based on its Price-To-Sales Ratio (8x) compared to the estimated Fair Price-To-Sales Ratio (3.8x).

Analyst Price Targets

What is the analyst 12-month forecast and do we have any statistical confidence in the consensus price target?

The above table shows the analyst 0ME forecast and predictions for the stock price in 12 month’s time.
DateShare PriceAverage 1Y Price TargetDispersionHighLow1Y Actual priceAnalysts
Current€38.89
€47.65
+22.5%
12.0%€54.74€33.03n/a10
Nov ’25€37.10
€46.54
+25.4%
12.7%€53.56€32.32n/a10
Oct ’25€38.57
€45.88
+19.0%
15.0%€58.72€31.62n/a10
Sep ’25€40.05
€45.71
+14.1%
14.8%€58.97€31.75n/a10
Aug ’25€49.84
€46.30
-7.1%
20.6%€59.66€25.70n/a9
Jul ’25€45.21
€44.12
-2.4%
23.1%€60.74€26.16n/a9
Jun ’25€37.04
€40.16
+8.4%
18.4%€50.92€25.93n/a8
May ’25€29.37
€37.79
+28.7%
17.0%€45.06€23.47n/a8
Apr ’25€31.26
€36.31
+16.1%
21.3%€44.68€23.27n/a9
Mar ’25€36.04
€36.31
+0.7%
21.3%€44.68€23.27n/a9
Feb ’25€29.80
€32.77
+10.0%
28.5%€44.11€17.46n/a9
Jan ’25€33.88
€25.28
-25.4%
14.7%€30.27€17.43n/a9
Dec ’24€21.68
€25.21
+16.3%
14.0%€30.25€17.42n/a10
Nov ’24€14.64
€24.66
+68.4%
13.6%€31.18€17.95€37.1010
Oct ’24€19.09
€24.51
+28.4%
15.1%€31.22€17.98€38.5710
Sep ’24€19.93
€23.42
+17.5%
15.9%€29.99€17.27€40.059
Aug ’24€21.58
€19.88
-7.9%
27.4%€29.66€9.89€49.849
Jul ’24€17.66
€19.70
+11.6%
29.4%€30.48€10.16€45.219
Jun ’24€13.92
€19.31
+38.8%
31.3%€29.99€10.00€37.048
May ’24€10.93
€24.97
+128.5%
23.1%€34.67€18.25€29.378
Apr ’24€13.27
€29.87
+125.1%
18.7%€39.83€19.45€31.268
Mar ’24€18.00
€29.87
+66.0%
18.7%€39.83€19.45€36.048
Feb ’24€25.81
€32.33
+25.2%
20.0%€46.02€22.09€29.808
Jan ’24€21.49
€33.06
+53.9%
24.0%€47.04€22.58€33.887
Dec ’23€23.35
€33.58
+43.8%
26.0%€48.44€23.25€21.686
Nov ’23n/a
€47.41
0%
16.4%€57.71€36.07€14.646

Analyst Forecast: Target price is less than 20% higher than the current share price.

Discover undervalued companies

Amneal Pharmaceuticals

US$2.6b

Develops, manufactures, markets, and distributes generics, injectables, biosimilars, and specialty branded pharmaceutical products worldwide.

2DT

US$7.70

7D

-4.3%

1Y

91.5%

Teva Pharmaceutical Industries

US$19.4b

Develops, manufactures, markets, and distributes generic medicines, specialty medicines, and biopharmaceutical products in North America, Europe, Israel, and internationally.

TEV

US$16.25

7D

2.5%

1Y

89.8%

Merck

US$252.6b

Operates as a healthcare company worldwide.

6MK

US$97.10

7D

6.7%

1Y

3.9%